세계의 비알코올성 지방간 질환(NAFLD) 시장(2023-2030년)

Global Nonalcoholic Fatty Liver Disease (NAFLD) Market - 2023-2030

US $ 4,350 ￦ 6,069,000

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850 ￦ 6,767,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850 ￦ 10,953,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비알코올성 지방간 질환(NAFLD)은 간에 지방이 축적되어 발생하는 다양한 증상을 일컫는 말입니다. 일반적으로 과체중이나 비만인 사람에게서 발견됩니다. 건강한 간에는 지방이 거의 없어야 합니다. 영국에서는 3명 중 1명꼴로 간에 지방이 거의 없는 초기 NAFLD로 평가되고 있습니다. 초기 NAFLD는 일반적으로 해를 끼치지는 않지만 악화되면 간경변을 포함한 심각한 간 손상을 초래할 수 있습니다.

현재 인슐린 감작제(티아졸리딘 계열 약물)와 항산화제(비타민 E)가 NAFLD/NASH에 매우 유리한 치료제로 여겨지고 있으며, 지질 저하제, 인슐린 감작제, 안지오텐신 수용체 길항제, n-3계 불포화지방산도 치료제로 채택되고 있습니다.

시장 역학: 촉진요인 및 억제요인

높은 유병률

비알코올성 지방간 질환(NAFLD)의 높은 유병률은 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 미국 국립 당뇨병, 소화기 및 신장 질환 연구소(NIDDK)는 NAFLD가 비만과 같은 특정 질병 및 장애, 제 2 형 당뇨병을 포함하여 비만과 관련이있을 수있는 증상을 가진 사람들에게 매우 일반적이라고 말합니다. 조사에 따르면 제2형 당뇨병 환자의 3분의 1에서 3분의 2가 NAFLD인 것으로 나타났습니다. 또한 조사에 따르면 NAFLD는 과체중 환자의 약 75%, 고도비만 환자의 90% 이상에서 발견된다고 합니다.

또한 미국 간재단에 따르면 미국에서는 약 1억 명이 비알코올성 지방간 질환을 앓고 있는 것으로 평가되고 있습니다. 비알코올성 지방간 질환(NAFLD)은 소아 간질환 중 가장 대표적인 질환으로 지난 20년간 2배로 증가했습니다.

엄격한 규제당국

신약 치료제를 승인하는 규제 당국의 엄격함은 세계 시장 성장을 저해할 것으로 예상됩니다. 또한, 높은 의약품 개발 비용과 치료 부작용도 예측 기간 동안 세계 시장 성장에 걸림돌이 될 것으로 예상됩니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 높은 유병률
  • 성장 억제요인
    • 엄격한 규제 당국
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• 상환 분석
• 특허 분석
• 파이프라인 분석
• 역학 분석
• SWOT 분석
• DMI 오피니언

제6장 COVID-19 분석

제7장 약제 클래스별

• 항산화제
• 지질저하제
• 인슐린 감작약
• 펜톡시필린
• 안지오텐신 수용체 차단제
• 기타

제8장 병기별

• 비알코올성 지방간염(NASH)
• 간경변
• 섬유증

제9장 투여 경로별

• 주사
• 경구
• 기타

제10장 유통 채널별

• 병원 약국
• 소매 약국
• 온라인 약국
• 기타

제11장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제12장 경쟁 상황

• 경쟁 시나리오
• 시장 상황/점유율 분석
• M&A 분석

제13장 기업 개요

• Pfizer Inc.
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• AstraZeneca
• Novartis AG
• Takeda Pharmaceutical Company Limited.
• Intercept Pharmaceuticals, Inc.
• F. Hoffmann-La Roche AG
• Merck & Co., Inc.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Akero Therapeutics, Inc.

제14장 부록

ksm

영문 목차

영문목차

Overview

Non-alcoholic fatty liver disease (NAFLD) is the term for a spectrum of conditions caused by a build-up of fat in the liver. It's usually seen in people who are overweight or obese. A healthy liver should contain little or no fat. It is assessed that nearly 1 in out of 3 individuals in the UK has premature phases of NAFLD where there exist little quantities of fat in their liver. Early-stage NAFLD does not usually induce any harm, but it can direct to severe liver damage, including cirrhosis if it gets worse.

Presently, insulin sensitizers (thiazolidinediones) and antioxidants (vitamin E) appear to be the highly advantageous therapeutic agents for NAFLD/NASH, and lipid-lowering drugs, Insulin sensitizers, angiotensin receptor blockers, and n-3 polyunsaturated fatty acids also have been employed in the treatment.

Market Dynamics: Drivers & Restraints

High Prevalence of Condition

The high prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) is expected to boost the global market growth during the forecast period. For instance, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NAFLD is highly typical in individuals who have certain diseases and disorders, such as obesity, and conditions that may be linked to obesity, including type 2 diabetes. Investigations indicate that one-third to two-thirds of individuals with type 2 diabetes have NAFLD. Research also indicates that NAFLD is present in around 75% of individuals who are overweight and in over 90% of individuals who have severe obesity.

Moreover, according to the American Liver Foundation, approximately 100 million people in the United States are assessed to have nonalcoholic fatty liver disease. Nonalcoholic Fatty Liver Disease (NAFLD), is the most typical condition of liver disorder in children and has increased two folds over the past 20 years.

Stringent Regulatory Authorities

The stringent regulatory authorities authorizing the new drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.

Segment Analysis

The global Nonalcoholic Fatty Liver Disease (NAFLD) market is segmented based on drug class, disease stage, route of administration, distribution channel and region.

Non-Alcoholic Steatohepatitis (NASH) Stage of NAFLD is Expected to Dominate Market

Owing to the increasing research approval from the FDA the Non-Alcoholic Steatohepatitis (NASH) Stage of NAFLD is expected to dominate the global market during the forecast period. For instance, in September 2023 Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), obtained the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) award for resmethrin to treat adult patients with NASH with liver fibrosis.

Moreover, in June 2023, Merck, obtained Fast Track Designation from the U.S. Food and Drug for Efinopegdutide, a technology transferred from the South Korean pharmaceutical corporation Hanmi Pharmaceutical Co., to treat nonalcoholic steatohepatitis (NASH). Similarly, in May 2022, Pfizer Inc. acquired the U.S. Food and Drug Administration (FDA) Fast Track designation for its investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Geographical Analysis

North America is Expected to Dominate the Global Market

The increasing research funding and investments in North America are expected to boost the regional market growth, thereby dominating the global market in the forecast period. For instance, in September 2022, Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical corporation committed to enhancing cardio-metabolic health, secured a $132 million Series B financing conducted by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. This financing is expected to additionally sustain the clinical advance of principal nominee HU6, a first-in-class Controlled Metabolic Accelerator (CMA) developed for the treatment of cardio-metabolic disorder by managing obesity, a direct driver of disorder.

Moreover, since there are no medications authorized by the U.S. Food and Drug Administration (FDA) for the treatment of NAFLD. A recent $9.57 million funding granted to researchers with the UC San Diego NAFLD Research Center at the University of California San Diego School of Medicine is expected to aid in the clinical trial to investigate new threatment choices for individuals with the condition.

COVID-19 Impact Analysis

The pandemic is estimated to have positively impacted the global market growth owing to an increase in treatment demand as Plasminogen activator inhibitor-1 is observed to be advanced in COVID-19 patients. While the level of PAI-1 is significantly elevated in fibrotic tissues, the lack of PAI-1 protects different organs from fibrosis in response to injury-related profibrotic signals.

Thus, PAI-1 is implicated in the pathology of fibrosis in different organs including the heart, lung, kidney, liver, and skin. This role of PAI-1 in COVID-19 liver injury is potentially interesting, especially in NAFLD patients, as elevated PAI-1 has been associated with NAFLD and NASH therefore, COVID-19-induced PAI-1 elevation aggravated NAFLD.

Market Segmentation

By Drug Class

• Antioxidants
• Lipid-Lowering Drugs
• Insulin sensitizers
• Pentoxifylline
• Angiotensin receptor blockers
• Others

By Disease Stage

• Non-Alcoholic Steatohepatitis (NASH)
• Cirrhosis
• Fibrosis

By Route of Administration

• Injectable
• Oral
• Other

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In April 2022, Oramed Pharmaceuticals Inc. acquired the patent termed "Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof" from the European Patent Office. They have produced oral protein delivery platform technology which protects therapeutic proteins in the digestive system.
• In March 2023 Akero Therapeutics, Inc., a clinical-stage corporation designing transformational therapies for patients with serious metabolic disorders and high unmet medical needs, declared positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and details of the anticipated SYNCHRONY Phase 3 efruxifermin schedule for the treatment of nonalcoholic steatohepatitis (NASH).

Competitive Landscape

The major global players in the market include: Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co., Inc., Abbvie Inc., And Gilead Sciences, Inc. among others.

Why Purchase the Report?

• To visualize the global Nonalcoholic Fatty Liver Disease (NAFLD) market segmentation based on drug class, disease stage, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Nonalcoholic Fatty Liver Disease (NAFLD) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Nonalcoholic Fatty Liver Disease (NAFLD) market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Disease Stage
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. High Prevalence of Condition
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent Regulatory Authorities
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. Pipeline Analysis
• 5.8. Epidemiology
• 5.9. SWOT Analysis
• 5.10. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Antioxidants*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Lipid-Lowering Drugs
• 7.4. Insulin sensitizers
• 7.5. Pentoxifylline
• 7.6. Angiotensin Receptor Blockers
• 7.7. Others

8. By Disease Stage

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  • 8.1.2. Market Attractiveness Index, By Disease Stage
• 8.2. Non-Alcoholic Steatohepatitis (NASH)*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cirrhosis
• 8.4. Fibrosis

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Injectable*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Oral
• 9.4. Other

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Pfizer Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. AstraZeneca
• 13.3. Novartis AG
• 13.4. Takeda Pharmaceutical Company Limited.
• 13.5. Intercept Pharmaceuticals, Inc.
• 13.6. F. Hoffmann-La Roche AG
• 13.7. Merck & Co., Inc.
• 13.8. AbbVie Inc.
• 13.9. Gilead Sciences, Inc.
• 13.10. Akero Therapeutics, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us

관련자료